Merck aims for prostate cancer dominance with 3 new phase 3 Keytruda studies
admin 14th February 2019 Uncategorised 0If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different. The company is adding a trio of late-stage studies to its Keytruda program, hoping they’ll deliver some new combo approvals.
More: Merck aims for prostate cancer dominance with 3 new phase 3 Keytruda studies
Source: fierce